Related Experiment Video

Updated: Nov 15, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

671

Methylphenidate exerts neuroprotective effects through the AMPK signaling pathway

P Li1, Y Huang1, Y Yang1

  • 1Department of Neurology, Hunan Provincial Brain Hospital, Changsha, China.

Human & Experimental Toxicology
|March 4, 2021
PubMed
Abstract

Insights

Methylphenidate (MPH) shows neuroprotective effects against cerebral ischemia-reperfusion injury by activating the AMPK pathway. This study suggests MPH as a potential therapeutic agent for stroke and related brain damage.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cell Biology

Background:

  • Cerebral ischemia is a leading cause of permanent adult disability globally.
  • Understanding reparative mechanisms is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the neuroprotective effects of methylphenidate (MPH) in cerebral ischemia-reperfusion injury.
  • To elucidate the underlying molecular mechanisms, particularly the role of the AMPK pathway.

Main Methods:

  • Established in vitro oxygen-glucose deprivation/reperfusion (OGD/R) and in vivo cerebral ischemia-reperfusion models in Sprague-Dawley rats.
  • Assessed cell viability (MTT assay), apoptosis (Annexin V/PI staining), protein expression (Western blot), cerebral infarction volume (TTC staining), and DNA damage (TUNEL assay).
  • Investigated the involvement of the AMPK/ACC pathway and the effect of an AMPK inhibitor.

Main Results:

  • MPH treatment significantly reduced OGD/R-induced cell damage, increasing cell viability and decreasing apoptosis.
  • MPH administration upregulated p-AMPK and p-ACC protein expression in OGD/R models.
  • Inhibition of AMPK largely abolished MPH's neuroprotective effects, indicating pathway involvement.
  • MPH treatment ameliorated cerebral ischemia-reperfusion injury and reduced apoptosis in brain tissues.

Conclusions:

  • Methylphenidate (MPH) demonstrates protective effects against oxidative stress and brain damage in cerebral ischemia-reperfusion models.
  • These neuroprotective properties are, at least partly, mediated by the activation of the AMPK pathway.
  • MPH emerges as a potential therapeutic agent for mitigating cerebral ischemia-reperfusion injury.
Keywords:
AMPK pathwayMethylphenidatecerebral ischemia-reperfusion injuryoxygen-glucose deprivation/reperfusion

More Related Videos

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.8K
Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

18.5K

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.3K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
305
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.1K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.8K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.3K
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
547